XML 19 R9.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue and Contract Acquisition Costs
 3 Months Ended
Mar. 31, 2025
Revenue from Contract with Customer [Abstract]  
Revenue and Contract Acquisition Costs Revenue and Contract Acquisition Costs
The following table summarizes the Company’s disaggregated revenue:
Three Months Ended March 31,
(in millions)20252024
U.S.
$401.7 $317.7 
International
152.4 115.3 
Total Omnipod products
554.1 433.0 
Drug Delivery14.9 8.7 
Total revenue$569.0 $441.7 
The percentages of total revenue for customers that represent 10% or more of total revenue were as follows:
Three Months Ended March 31,

20252024
Distributor A25 %25 %
Distributor B24 %31 %
Distributor C
23 %22 %
Deferred revenue related to unsatisfied performance obligations was included in the following consolidated balance sheet accounts in the amounts shown:
(in millions)
March 31, 2025December 31, 2024
Accrued expenses and other current liabilities$15.4 $12.0 
Other liabilities0.7 2.0 
Total deferred revenue$16.1 $14.0 
Revenue recognized from amounts included in deferred revenue at the beginning of each respective period was as follows:
Three Months Ended March 31,
(in millions)20252024
Deferred revenue recognized$5.6 $3.1 
Contract acquisition costs, representing capitalized commission costs related to new customers, net of amortization, were included in the following consolidated balance sheet captions in the amounts shown:
(in millions)March 31, 2025December 31, 2024
Prepaid expenses and other current assets$21.4 $20.1 
Other assets43.7 40.8 
Total capitalized contract acquisition costs, net$65.1 $60.9 
The Company recognized $5.1 million and $4.2 million of amortization of capitalized contract acquisition costs during the three months ended March 31, 2025 and 2024, respectively.